AbCellera and Eli Lilly Collaborate to Co-develop Antibody Therapies Targeting COVID-19

 AbCellera and Eli Lilly Collaborate to Co-develop Antibody Therapies Targeting COVID-19

AbCellera and Eli Lilly Collaborate to Co-develop Antibody Therapies Targeting COVID-19

Shots:

  • The alliance will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA P3 program with Eli Lilly’s development & manufacturing capabilities. The companies will equally share the initial development cost while Lilly will be solely responsible for further development, manufacturing & distribution activities
  • The companies have identified ~500+ unique Ab isolated from one of the first US patients who recovered from COVID-19, later they screen these Ab to find the most effective Abs, neutralizing SARS-CoV-2
  • Selected Abs will be expressed in collaboration with VRC at NIAID and pending agreement with NIAID will be tested Abs for their ability to neutralize the virus

Click here ­to­ read full press release/ article | Ref: Eli Lilly  | Image: GEN

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post